Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase.
Tryptophan depletion resulting from indoleamine 2,3-dioxygenase (IDO) activity within the kynurenine pathway is one of the most prominent gamma interferon (IFN-gamma)-inducible antimicrobial effector mechanisms in human cells. On the other hand, nitric oxide (NO) produced by the inducible isoform of NO synthase (iNOS) serves a more immunoregulatory role in human cells and thereby interacts with tryptophan depletion in a number of ways. We investigated the effects of NO on IDO gene transcription, protein synthesis, and enzyme activity as well as on IDO-mediated bacteriostasis in the human epithelial cell line RT4. IFN-gamma-stimulated RT4 cells were able to inhibit the growth of Staphylococcus aureus in an IDO-mediated fashion, and this bacteriostatic effect was abolished by endogenously produced NO. These findings were supported by experiments which showed that IDO activity in extracts of IFN-gamma-stimulated cells is inhibited by the chemical NO donors diethylenetriamine diazeniumdiolate, S-nitroso-L-cysteine, and S-nitroso-N-acetyl-D,L-penicillamine. Furthermore, we found that both endogenous and exogenous NO strongly reduced the level of IDO protein content in RT4 cells. This effect was not due to a decrease in IDO gene transcription or mRNA stability. By using inhibitors of proteasomal proteolytic activity, we showed that NO production led to an accelerated degradation of IDO protein in the proteasome. This is the first report, to our knowledge, that demonstrates that the IDO is degraded by the proteasome and that NO has an effect on IDO protein stability.
Hucke
Christian
C
Institute for Medical Microbiology, Heinrich Heine University, Düsseldorf, Germany.
MacKenzie
Colin R
CR
Adjogble
Koku D Z
KD
Takikawa
Osamu
O
Däubener
Walter
W
D000900:Anti-Bacterial Agents / Q000378:metabolism; D002460:Cell Line; D003546:Cysteine Endopeptidases / Q000378:metabolism; D004795:Enzyme Stability; D006801:Humans; D066298:In Vitro Techniques; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007371:Interferon-gamma / Q000378:metabolism*; D009097:Multienzyme Complexes / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex; D020871:RNA Stability; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013211:Staphylococcus aureus / Q000276:immunology*; D014366:Tryptophan Oxygenase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D000900:Anti-Bacterial Agents; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D009097:Multienzyme Complexes; D020030:Nitric Oxide Donors; D012333:RNA, Messenger; D009569:Nitric Oxide; D007371:Interferon-gamma; D014366:Tryptophan Oxygenase; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex